{"abstracts-retrieval-response": {
    "item": {
        "ait:process-info": {
            "ait:status": {
                "@state": "update",
                "@type": "core",
                "@stage": "S300"
            },
            "ait:date-delivered": {
                "@day": "01",
                "@timestamp": "2022-03-01T08:09:32.000032-05:00",
                "@year": "2022",
                "@month": "03"
            },
            "ait:date-sort": {
                "@day": "01",
                "@year": "2021",
                "@month": "11"
            }
        },
        "bibrecord": {
            "head": {
                "author-group": {
                    "affiliation": {
                        "country": "Thailand",
                        "@afid": "60028190",
                        "@country": "tha",
                        "city": "Bangkok",
                        "organization": [
                            {"$": "Department of Social and Administrative Pharmacy"},
                            {"$": "Faculty of Pharmaceutical Sciences"},
                            {"$": "Chulalongkorn University"}
                        ],
                        "affiliation-id": {
                            "@afid": "60028190",
                            "@dptid": "108180929"
                        },
                        "@affiliation-instance-id": "2016946464-9e11e1f60e5e57e9ede150ade52a928a",
                        "ce:source-text": "Department of Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand",
                        "@dptid": "108180929"
                    },
                    "author": [
                        {
                            "ce:given-name": "Parnnaphat",
                            "preferred-name": {
                                "ce:given-name": "Parnnaphat",
                                "ce:initials": "P.",
                                "ce:surname": "Luksameesate",
                                "ce:indexed-name": "Luksameesate P."
                            },
                            "@author-instance-id": "2016946464-540b328f708d83e5b2b10542aa3690c9",
                            "@seq": "1",
                            "ce:initials": "P.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Luksameesate",
                            "@auid": "57458762900",
                            "ce:indexed-name": "Luksameesate P."
                        },
                        {
                            "ce:given-name": "Suthira",
                            "preferred-name": {
                                "ce:given-name": "Suthira",
                                "ce:initials": "S.",
                                "ce:surname": "Taychakhoonavudh",
                                "ce:indexed-name": "Taychakhoonavudh S."
                            },
                            "@author-instance-id": "2016946464-fdfadbe01fecf9724c84efc23f1146a8",
                            "@seq": "2",
                            "ce:initials": "S.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Taychakhoonavudh",
                            "@auid": "56196894400",
                            "ce:indexed-name": "Taychakhoonavudh S."
                        }
                    ]
                },
                "citation-title": "Health Technology Assessment (HTA) evidence, regulatory classification and reimbursement of medicine: The case of glucosamine",
                "abstracts": "Â© 2021 The Author(s). Published by Oxford University Press on behalf of the Royal Pharmaceutical Society. All rights reservedObjectives: To examine the relationship among Health Technology Assessment (HTA) evidence, regulatory classification and reimbursement of health products using glucosamine as a case study. Data of HTA evidence, regulatory classification and reimbursement of glucosamine from 13 countries were extracted from official government websites and peer-reviewed journal articles. Role and responsibility of HTA in each country along as well as the regulatory approval process and reimbursement status of health products were reviewed. The case of glucosamine was then analysed to explore the regulatory classification, reimbursement and its HTA evidence from past to present. Key findings: For regulatory classification, we found that glucosamine is classified as either medicine (9 from 13 countries) or a dietary supplement (4 from 13 countries) depends on where glucosamine is seeking its market approval. Reimbursement also differs among the countries. We summarized the key factors that could be the cause of these variations. First, the clinical evidence of glucosamine is still in question especially its efficacy and as a results its cost-effectiveness. This evidence is important for policy consideration. Secondly, different level of HTA approach in each healthcare system and country context effect on how HTA evidence is utilized and synthesized. Lastly, company's strategic positioning is the first key stakeholder to decide whether their product would be registered as medicine or dietary supplement. Summary: The variation of HTA evidence in a diverse healthcare system affects regulatory classifications and reimbursement. This can result in different levels of patient access to health products.",
                "correspondence": {
                    "affiliation": {
                        "country": "Thailand",
                        "@country": "tha",
                        "city": "Bangkok",
                        "organization": [
                            {"$": "Department of Social and Administrative Pharmacy"},
                            {"$": "Faculty of Pharmaceutical Sciences"},
                            {"$": "Chulalongkorn University"}
                        ],
                        "ce:source-text": "Department of Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand"
                    },
                    "person": {
                        "ce:given-name": "Suthira",
                        "ce:initials": "S.",
                        "ce:surname": "Taychakhoonavudh",
                        "ce:indexed-name": "Taychakhoonavudh S."
                    }
                },
                "citation-info": {
                    "author-keywords": {"author-keyword": [
                        {
                            "$": "glucosamine",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "Health Technology Assessment (HTA)",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "osteoarthritis",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "regulatory classification",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "reimbursement",
                            "@xml:lang": "eng",
                            "@original": "y"
                        }
                    ]},
                    "citation-type": {"@code": "re"},
                    "citation-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    },
                    "abstract-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    }
                },
                "source": {
                    "sourcetitle-abbrev": "J. Pharm. Health. Serv. Res.",
                    "website": {"ce:e-address": {
                        "$": "https://academic.oup.com/jphsr",
                        "@type": "email"
                    }},
                    "@country": "gbr",
                    "translated-sourcetitle": {
                        "$": "Journal of Pharmaceutical Health Services Research",
                        "@xml:lang": "eng"
                    },
                    "issn": [
                        {
                            "$": "17598893",
                            "@type": "electronic"
                        },
                        {
                            "$": "17598885",
                            "@type": "print"
                        }
                    ],
                    "volisspag": {
                        "voliss": {
                            "@volume": "12",
                            "@issue": "4"
                        },
                        "pagerange": {
                            "@first": "600",
                            "@last": "606"
                        }
                    },
                    "@type": "j",
                    "publicationyear": {"@first": "2021"},
                    "publisher": {"publishername": "Oxford University Press"},
                    "sourcetitle": "Journal of Pharmaceutical Health Services Research",
                    "@srcid": "19700201423",
                    "publicationdate": {
                        "month": "11",
                        "year": "2021",
                        "date-text": {
                            "@xfab-added": "true",
                            "$": "1 November 2021"
                        },
                        "day": "01"
                    }
                },
                "enhancement": {
                    "classificationgroup": {"classifications": [
                        {
                            "@type": "EMCLASS",
                            "classification": [
                                {
                                    "classification-code": "36",
                                    "classification-description": "Health Policy, Economics and Management"
                                },
                                {
                                    "classification-code": "37",
                                    "classification-description": "Drug Literature Index"
                                }
                            ]
                        },
                        {
                            "@type": "ASJC",
                            "classification": [
                                {"$": "3611"},
                                {"$": "2001"},
                                {"$": "3001"}
                            ]
                        },
                        {
                            "@type": "SUBJABBR",
                            "classification": [
                                {"$": "HEAL"},
                                {"$": "ECON"},
                                {"$": "PHAR"}
                            ]
                        }
                    ]},
                    "chemicalgroup": {"chemicals": {
                        "@source": "esbd",
                        "chemical": {
                            "cas-registry-number": [
                                {"$": "3416-24-8"},
                                {"$": "4607-22-1"}
                            ],
                            "chemical-name": "glucosamine"
                        }
                    }}
                }
            },
            "item-info": {
                "copyright": {
                    "$": "Copyright 2022 Elsevier B.V., All rights reserved.",
                    "@type": "Elsevier"
                },
                "dbcollection": [
                    {"$": "EMBASE"},
                    {"$": "REAXYSCAR"},
                    {"$": "SCOPUS"},
                    {"$": "Scopusbase"}
                ],
                "history": {"date-created": {
                    "@day": "28",
                    "@timestamp": "BST 10:40:51",
                    "@year": "2022",
                    "@month": "02"
                }},
                "itemidlist": {
                    "itemid": [
                        {
                            "$": "2016946464",
                            "@idtype": "PUI"
                        },
                        {
                            "$": "938642395",
                            "@idtype": "CAR-ID"
                        },
                        {
                            "$": "20220162707",
                            "@idtype": "EMBASE"
                        },
                        {
                            "$": "20220505731",
                            "@idtype": "REAXYSCAR"
                        },
                        {
                            "$": "20220647183",
                            "@idtype": "SCOPUS"
                        },
                        {
                            "$": "20210016014721",
                            "@idtype": "TPA-ID"
                        },
                        {
                            "$": "85124908972",
                            "@idtype": "SCP"
                        },
                        {
                            "$": "85124908972",
                            "@idtype": "SGR"
                        }
                    ],
                    "ce:doi": "10.1093/jphsr/rmab058"
                }
            },
            "tail": {"bibliography": {
                "@refcount": "58",
                "reference": [
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Thai Food and Drug Administration. The Roles and Responsibilities of Thai FDA. https://www.fda.moph.go.th/sites/fda_en/SitePages/Roles.aspx (7 March 2020, date last accessed).",
                        "@id": "1",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.fda.moph.go.th/sites/fda_en/SitePages/Roles.aspx",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85124884366",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "(7 March 2020, date last accessed)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Thai Food and Drug Administration",
                                "ce:indexed-name": "Thai Food and Drug Administration"
                            }},
                            "ref-sourcetitle": "The Roles and Responsibilities of Thai FDA"
                        },
                        "ce:source-text": "Thai Food and Drug Administration. The Roles and Responsibilities of Thai FDA. https://www.fda.moph.go.th/sites/fda_en/SitePages/Roles.aspx (7 March 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Institute for Clinical and Economic Review (ICER). Guide to Understanding Health Technology Assessment (HTA). http://icer-review.org/wp-content/ uploads/2018/08/ICER-Guide-to-Understanding-Health-Technology-Assessment-6.19.18.pdf (15 November 2020, date last accessed).",
                        "@id": "2",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "http://icer-review.org/wp-content/uploads/2018/08/ICER-Guide-to-Understanding-Health-Technology-Assessment-6.19.18.pdf",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85124903762",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "(15 November 2020, date last accessed)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Institute for Clinical and Economic Review (ICER)",
                                "ce:indexed-name": "Institute for Clinical and Economic Review (ICER)"
                            }},
                            "ref-sourcetitle": "Guide to Understanding Health Technology Assessment (HTA)"
                        },
                        "ce:source-text": "Institute for Clinical and Economic Review (ICER). Guide to Understanding Health Technology Assessment (HTA). http://icer-review.org/wp-content/ uploads/2018/08/ICER-Guide-to-Understanding-Health-Technology-Assessment-6.19.18.pdf (15 November 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Luce BR, Drummond M, JÃ¶nsson B et al. EBM, HTA, and CER: clearing the confusion. Milbank Q 2010; 88: 256-76. http://doi. org/10.1111/j.1468-0009.2010.00598.x",
                        "@id": "3",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2010"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.1111/j.1468-0009.2010.00598.x",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "EBM, HTA, and CER: clearing the confusion"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1111/j.1468-0009.2010.00598.x",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "77953777057",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "88"},
                                "pagerange": {
                                    "@first": "256",
                                    "@last": "276"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "BR",
                                        "@_fa": "true",
                                        "ce:surname": "Luce",
                                        "ce:indexed-name": "Luce BR"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Drummond",
                                        "ce:indexed-name": "Drummond M"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "B",
                                        "@_fa": "true",
                                        "ce:surname": "JÃ¶nsson",
                                        "ce:indexed-name": "Jonsson B"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Milbank Q"
                        },
                        "ce:source-text": "Luce BR, Drummond M, JÃ¶nsson B et al. EBM, HTA, and CER: clearing the confusion. Milbank Q 2010; 88: 256-76. http://doi. org/10.1111/j.1468-0009.2010.00598.x"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Garrison L. An Introduction to Health Technology Assessment in the U.S. and Canada: Possible Lessons and Implications for Taiwan? http://globalmedicines. org/wordpress/wp-content/uploads/2014/01/Garrison-HTA-US-CAN-July-5-2011-FINAL-7-5.pdf?1478792404 (8 November 2020, date last accessed).",
                        "@id": "4",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "http://globalmedicines.org/wordpress/wp-content/uploads/2014/01/Garrison-HTA-US-CAN-July-5-2011-FINAL-7-5.pdf?1478792404",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85124891017",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "(8 November 2020, date last accessed)",
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "L.",
                                "@_fa": "true",
                                "ce:surname": "Garrison",
                                "ce:indexed-name": "Garrison L."
                            }]},
                            "ref-sourcetitle": "An Introduction to Health Technology Assessment in the U.S. and Canada: Possible Lessons and Implications for Taiwan?"
                        },
                        "ce:source-text": "Garrison L. An Introduction to Health Technology Assessment in the U.S. and Canada: Possible Lessons and Implications for Taiwan? http://globalmedicines. org/wordpress/wp-content/uploads/2014/01/Garrison-HTA-US-CAN-July-5-2011-FINAL-7-5.pdf?1478792404 (8 November 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "European Commission (EC). Food Supplements. https://ec.europa.eu/ food/safety/labelling_nutrition/supplements_en (19 October 2020, date last accessed).",
                        "@id": "5",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://ec.europa.eu/food/safety/labelling_nutrition/supplements_en",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "84973433669",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "(19 October 2020, date last accessed)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "European Commission (EC)",
                                "ce:indexed-name": "European Commission (EC)"
                            }},
                            "ref-sourcetitle": "Food Supplements"
                        },
                        "ce:source-text": "European Commission (EC). Food Supplements. https://ec.europa.eu/ food/safety/labelling_nutrition/supplements_en (19 October 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "The United States Food and Drug Administration (USFDA). Dietary Supplements Guidance Documents & Regulatory Information. https:// www.fda.gov/food/guidance-documents-regulatory-information-topicfood-and-dietary-supplements/dietary-supplements-guidance-documentsregulatory-information#labeling (25 August 2020, date last accessed).",
                        "@id": "6",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.fda.gov/food/guidance-documents-regulatory-information-topicfood-and-dietary-supplements/dietary-supplements-guidance-documentsregulatory-information#labeling",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85055863383",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "The United States Food and Drug Administration (USFDA). (25 August 2020, date last accessed)",
                            "ref-sourcetitle": "Dietary Supplements Guidance Documents & Regulatory Information"
                        },
                        "ce:source-text": "The United States Food and Drug Administration (USFDA). Dietary Supplements Guidance Documents & Regulatory Information. https:// www.fda.gov/food/guidance-documents-regulatory-information-topicfood-and-dietary-supplements/dietary-supplements-guidance-documentsregulatory-information#labeling (25 August 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Allen N, Pichler F, Wang T et al. Development of archetypes for nonranking classification and comparison of European National Health Technology Assessment systems. Health Policy 2013; 113: 305-12. http:// doi.org/10.1016/j.healthpol.2013.09.007",
                        "@id": "7",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.1016/j.healthpol.2013.09.007",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Development of archetypes for nonranking classification and comparison of European National Health Technology Assessment systems"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1016/j.healthpol.2013.09.007",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "84888057001",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "113"},
                                "pagerange": {
                                    "@first": "305",
                                    "@last": "312"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N",
                                        "@_fa": "true",
                                        "ce:surname": "Allen",
                                        "ce:indexed-name": "Allen N"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "F",
                                        "@_fa": "true",
                                        "ce:surname": "Pichler",
                                        "ce:indexed-name": "Pichler F"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang T"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Health Policy"
                        },
                        "ce:source-text": "Allen N, Pichler F, Wang T et al. Development of archetypes for nonranking classification and comparison of European National Health Technology Assessment systems. Health Policy 2013; 113: 305-12. http:// doi.org/10.1016/j.healthpol.2013.09.007"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "The University of Southern California Schaeffer Center. Health Technology Assessment for the U.S. Healthcare System Background Paper. https:// healthpolicy.usc.edu/wp-content/uploads/2020/02/Health-Technology-Assessment-for-the-U.S.-Healthcare-System_Background-Paper.pdf (2 October 2020, date last accessed).",
                        "@id": "8",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://healthpolicy.usc.edu/wp-content/uploads/2020/02/Health-Technology-Assessment-for-the-U.S.-Healthcare-System_Background-Paper.pdf",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85124873057",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "The University of Southern California Schaeffer Center. (2 October 2020, date last accessed)",
                            "ref-sourcetitle": "Health Technology Assessment for the U.S. Healthcare System Background Paper"
                        },
                        "ce:source-text": "The University of Southern California Schaeffer Center. Health Technology Assessment for the U.S. Healthcare System Background Paper. https:// healthpolicy.usc.edu/wp-content/uploads/2020/02/Health-Technology-Assessment-for-the-U.S.-Healthcare-System_Background-Paper.pdf (2 October 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Towheed T, Maxwell L, Anastassiades TP et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005; 2: 1-77. http:// doi.org/ 10.1002/14651858.CD002946.pub2",
                        "@id": "9",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2005"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.1002/14651858.CD002946.pub2",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Glucosamine therapy for treating osteoarthritis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1002/14651858.CD002946.pub2",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "0035221023",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "2"},
                                "pagerange": {
                                    "@first": "1",
                                    "@last": "77"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "T",
                                        "@_fa": "true",
                                        "ce:surname": "Towheed",
                                        "ce:indexed-name": "Towheed T"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L",
                                        "@_fa": "true",
                                        "ce:surname": "Maxwell",
                                        "ce:indexed-name": "Maxwell L"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "TP",
                                        "@_fa": "true",
                                        "ce:surname": "Anastassiades",
                                        "ce:indexed-name": "Anastassiades TP"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cochrane Database Syst Rev"
                        },
                        "ce:source-text": "Towheed T, Maxwell L, Anastassiades TP et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005; 2: 1-77. http:// doi.org/ 10.1002/14651858.CD002946.pub2"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Mohan CP. Glucosamine Sulfate. http://www.webmd.com/vitamins-andsupplements/ glucosamine-sulfate-uses-and-risks#2 (18 February 2020, date last accessed).",
                        "@id": "10",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "http://www.webmd.com/vitamins-andsupplements/glucosamine-sulfate-uses-and-risks#2",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "84906664704",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "(18 February 2020, date last accessed)",
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "CP.",
                                "@_fa": "true",
                                "ce:surname": "Mohan",
                                "ce:indexed-name": "Mohan CP."
                            }]},
                            "ref-sourcetitle": "Glucosamine Sulfate"
                        },
                        "ce:source-text": "Mohan CP. Glucosamine Sulfate. http://www.webmd.com/vitamins-andsupplements/ glucosamine-sulfate-uses-and-risks#2 (18 February 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Sibbritt D, Adams J, Lui CW et al. Who uses glucosamine and why? A study of 266,848 Australians aged 45 years and older. PLoS One 2012; 7: e41540. http://doi.org/10.1371/journal.pone.0041540",
                        "@id": "11",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2012"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.1371/journal.pone.0041540",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Who uses glucosamine and why? A study of 266,848 Australians aged 45 years and older"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1371/journal.pone.0041540",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "84864421796",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "7"},
                                "pagerange": {"@first": "e41540"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D",
                                        "@_fa": "true",
                                        "ce:surname": "Sibbritt",
                                        "ce:indexed-name": "Sibbritt D"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J",
                                        "@_fa": "true",
                                        "ce:surname": "Adams",
                                        "ce:indexed-name": "Adams J"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "CW",
                                        "@_fa": "true",
                                        "ce:surname": "Lui",
                                        "ce:indexed-name": "Lui CW"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "PLoS One"
                        },
                        "ce:source-text": "Sibbritt D, Adams J, Lui CW et al. Who uses glucosamine and why? A study of 266,848 Australians aged 45 years and older. PLoS One 2012; 7: e41540. http://doi.org/10.1371/journal.pone.0041540"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Group Health Incorporated (GHI). HIP Health Plan of New York and HIP Insurance Company of New York, EmblemHealth Medicare HMO Formulary 2018 (List of Covered Drugs). https://www.emblemhealth. com/Our-Plans/Medicare/2018-Important-Plan-Documents (1 November 2020, date last accessed).",
                        "@id": "12",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.emblemhealth.com/Our-Plans/Medicare/2018-Important-Plan-Documents",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85124904590",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "(1 November 2020, date last accessed)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Group Health Incorporated (GHI)",
                                "ce:indexed-name": "Group Health Incorporated (GHI)"
                            }},
                            "ref-sourcetitle": "HIP Health Plan of New York and HIP Insurance Company of New York, EmblemHealth Medicare HMO Formulary 2018 (List of Covered Drugs)"
                        },
                        "ce:source-text": "Group Health Incorporated (GHI). HIP Health Plan of New York and HIP Insurance Company of New York, EmblemHealth Medicare HMO Formulary 2018 (List of Covered Drugs). https://www.emblemhealth. com/Our-Plans/Medicare/2018-Important-Plan-Documents (1 November 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Thai Food and Drug Administration. Product Search. http://porta.fda. moph.go.th/FDA_SEARCH_ALL/MAIN/SEARCH_CENTER_MAIN. aspx (23 September 2020, date last accessed).",
                        "@id": "13",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "http://porta.fda.moph.go.th/FDA_SEARCH_ALL/MAIN/SEARCH_CENTER_MAIN.aspx",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "84956879812",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "(23 September 2020, date last accessed)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Thai Food and Drug Administration",
                                "ce:indexed-name": "Thai Food and Drug Administration"
                            }},
                            "ref-sourcetitle": "Product Search"
                        },
                        "ce:source-text": "Thai Food and Drug Administration. Product Search. http://porta.fda. moph.go.th/FDA_SEARCH_ALL/MAIN/SEARCH_CENTER_MAIN. aspx (23 September 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "The United States Food and Drug Administration (USFDA). Dietary Supplements: What You Need to Know. https://www.fda.gov/Food/ DietarySupplements/UsingDietarySupplements/ucm109760.htm (3 June 2020, date last accessed).",
                        "@id": "14",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.fda.gov/Food/DietarySupplements/UsingDietarySupplements/ucm109760.htm",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "84880844901",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "The United States Food and Drug Administration (USFDA). (3 June 2020, date last accessed)",
                            "ref-sourcetitle": "Dietary Supplements: What You Need to Know"
                        },
                        "ce:source-text": "The United States Food and Drug Administration (USFDA). Dietary Supplements: What You Need to Know. https://www.fda.gov/Food/ DietarySupplements/UsingDietarySupplements/ucm109760.htm (3 June 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Medicines and Healthcare Products Regulatory Agency (MHRA). Change in the Classification of Certain Glucosamine Products. https://www.gov. uk/government/news/change-in-the-classification-of-certain-glucosamineproducts (1 November 2020, date last accessed).",
                        "@id": "15",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.gov.uk/government/news/change-in-the-classification-of-certain-glucosamineproducts",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85124887319",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "(1 November 2020, date last accessed)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Medicines and Healthcare Products Regulatory Agency (MHRA)",
                                "ce:indexed-name": "Medicines and Healthcare Products Regulatory Agency (MHRA)"
                            }},
                            "ref-sourcetitle": "Change in the Classification of Certain Glucosamine Products"
                        },
                        "ce:source-text": "Medicines and Healthcare Products Regulatory Agency (MHRA). Change in the Classification of Certain Glucosamine Products. https://www.gov. uk/government/news/change-in-the-classification-of-certain-glucosamineproducts (1 November 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Pharmaceutical Benefits Advisory Committee (PBAC). A-Z Medicine Listing. http://www.pbs.gov.au/browse/medicine-listing (27 June 2020, date last accessed).",
                        "@id": "16",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "http://www.pbs.gov.au/browse/medicine-listing",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "84875234642",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "(27 June 2020, date last accessed)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Pharmaceutical Benefits Advisory Committee (PBAC)",
                                "ce:indexed-name": "Pharmaceutical Benefits Advisory Committee (PBAC)"
                            }},
                            "ref-sourcetitle": "A-Z Medicine Listing"
                        },
                        "ce:source-text": "Pharmaceutical Benefits Advisory Committee (PBAC). A-Z Medicine Listing. http://www.pbs.gov.au/browse/medicine-listing (27 June 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Government of Canada. Category Specific Guidance for Temporary Marketing Authorization: Supplemented Food. https://www.canada.ca/ en/health-canada/services/food-nutrition/legislation-guidelines/guidancedocuments/ category-specific-guidance-temporary-marketing-authorizationsupplemented-food.html (22 September 2020, date last accessed).",
                        "@id": "17",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.canada.ca/en/health-canada/services/food-nutrition/legislation-guidelines/guidancedocuments/category-specific-guidance-temporary-marketing-authorizationsupplemented-food.html",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85073397833",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "(22 September 2020, date last accessed)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Government of Canada",
                                "ce:indexed-name": "Government of Canada"
                            }},
                            "ref-sourcetitle": "Category Specific Guidance for Temporary Marketing Authorization: Supplemented Food"
                        },
                        "ce:source-text": "Government of Canada. Category Specific Guidance for Temporary Marketing Authorization: Supplemented Food. https://www.canada.ca/ en/health-canada/services/food-nutrition/legislation-guidelines/guidancedocuments/ category-specific-guidance-temporary-marketing-authorizationsupplemented-food.html (22 September 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Health Canada. Natural Health Products Ingredients Database. http:// webprod.hc-sc.gc.ca/nhpid-bdipsn/ingredsReq.do?srchRchTxt=glucosam ine&srchRchRole=-1&mthd=Search&lang=eng (21 June 2020, date last accessed).",
                        "@id": "18",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "http://webprod.hc-sc.gc.ca/nhpid-bdipsn/ingredsReq.do?srchRchTxt=glucosamine&srchRchRole=-1&mthd=Search&lang=eng",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "84878030334",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "Health Canada. (21 June 2020, date last accessed)",
                            "ref-sourcetitle": "Natural Health Products Ingredients Database"
                        },
                        "ce:source-text": "Health Canada. Natural Health Products Ingredients Database. http:// webprod.hc-sc.gc.ca/nhpid-bdipsn/ingredsReq.do?srchRchTxt=glucosam ine&srchRchRole=-1&mthd=Search&lang=eng (21 June 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Danish Medicines Agency. Medicinpriser.dk. https://www.medicinpriser. dk/default.aspx?lng=2 (7 June 2020, date last accessed).",
                        "@id": "19",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.medicinpriser.dk/default.aspx?lng=2",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85124891569",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "(7 June 2020, date last accessed)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Danish Medicines Agency",
                                "ce:indexed-name": "Danish Medicines Agency"
                            }},
                            "ref-sourcetitle": "Medicinpriser.dk"
                        },
                        "ce:source-text": "Danish Medicines Agency. Medicinpriser.dk. https://www.medicinpriser. dk/default.aspx?lng=2 (7 June 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "L'Agence nationale de sÃ©curitÃ© du mÃ©dicament et des produits de santÃ© (ANSM). Liste des mÃ©dicaments commercialisÃ©s en France au. http://ansm. sante.fr/searchengine/general_search?SearchText=essential&rubrique=Lis tes%20et%20r%C3%A9pertoires%20%20-%20M%C3%A9dicaments (30 July 2020, date last accessed).",
                        "@id": "20",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "http://ansm.sante.fr/searchengine/general_search?SearchText=essential&rubrique=Listes%20et%20r%C3%A9pertoires%20%20-%20M%C3%A9dicaments",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85124880176",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "L'Agence nationale de sÃ©curitÃ© du mÃ©dicament et des produits de santÃ© (ANSM). (30 July 2020, date last accessed)",
                            "ref-sourcetitle": "Liste des mÃ©dicaments commercialisÃ©s en France au"
                        },
                        "ce:source-text": "L'Agence nationale de sÃ©curitÃ© du mÃ©dicament et des produits de santÃ© (ANSM). Liste des mÃ©dicaments commercialisÃ©s en France au. http://ansm. sante.fr/searchengine/general_search?SearchText=essential&rubrique=Lis tes%20et%20r%C3%A9pertoires%20%20-%20M%C3%A9dicaments (30 July 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Medical, Economic and Public Health Assessment Division. OSAFLEXAN 1178 mg, Oral Powder for Solution in Single-Dose Sachets. https://www. has-sante.fr/portail/upload/docs/application/pdf/2014-05/osaflexan_ ct13087.pdf (19 July 2020, date last accessed).",
                        "@id": "21",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.has-sante.fr/portail/upload/docs/application/pdf/2014-05/osaflexan_ct13087.pdf",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85124897383",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "(19 July 2020, date last accessed)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Medical, Economic and Public Health Assessment Division",
                                "ce:indexed-name": "Medical, Economic and Public Health Assessment Division"
                            }},
                            "ref-sourcetitle": "OSAFLEXAN 1178 mg, Oral Powder for Solution in Single-Dose Sachets"
                        },
                        "ce:source-text": "Medical, Economic and Public Health Assessment Division. OSAFLEXAN 1178 mg, Oral Powder for Solution in Single-Dose Sachets. https://www. has-sante.fr/portail/upload/docs/application/pdf/2014-05/osaflexan_ ct13087.pdf (19 July 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Common European Drug Database (CEDD). Data by Country: Ireland 2018. http://cedd.oep.hu/drugs.tib?s=drug-database&mode=country&f=cedddrug1&id=8lkdbdqvvfq2glq8&portallang=en&IE_currentletter=G&actualcountry=IE &opage=1&validity=20100102&pages=60 (16 May 2020, date last accessed).",
                        "@id": "22",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "http://cedd.oep.hu/drugs.tib?s=drug-database&mode=country&f=cedddrug1&id=8lkdbdqvvfq2glq8&portallang=en&IE_currentletter=G&actualcountry=IE&opage=1&validity=20100102&pages=60",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85124885423",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "(16 May 2020, date last accessed)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Common European Drug Database (CEDD)",
                                "ce:indexed-name": "Common European Drug Database (CEDD)"
                            }},
                            "ref-sourcetitle": "Data by Country: Ireland 2018"
                        },
                        "ce:source-text": "Common European Drug Database (CEDD). Data by Country: Ireland 2018. http://cedd.oep.hu/drugs.tib?s=drug-database&mode=country&f=cedddrug1&id=8lkdbdqvvfq2glq8&portallang=en&IE_currentletter=G&actualcountry=IE &opage=1&validity=20100102&pages=60 (16 May 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Health Service Executive. List of Reimbursable Items https://www.hse.ie/ eng/staff/pcrs/items/reimburse.html (15 May 2020, date last accessed).",
                        "@id": "23",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.hse.ie/eng/staff/pcrs/items/reimburse.html",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85124887346",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "(15 May 2020, date last accessed)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Health Service Executive",
                                "ce:indexed-name": "Health Service Executive"
                            }},
                            "ref-sourcetitle": "List of Reimbursable Items"
                        },
                        "ce:source-text": "Health Service Executive. List of Reimbursable Items https://www.hse.ie/ eng/staff/pcrs/items/reimburse.html (15 May 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Common European Drug Database (CEDD). Data by Country: Norway. http://cedd.oep.hu/drugs.tib?s=drug-database&mode=country&f=cedddr ug1&id=8lkdbdqvvfq2glq8&portallang=en&NO_currentletter=Galcountry=NO&opage=2 (8 July 2020, date last accessed).",
                        "@id": "24",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "http://cedd.oep.hu/drugs.tib?s=drug-database&mode=country&f=cedddrug1&id=8lkdbdqvvfq2glq8&portallang=en&NO_currentletter=Galcountry=NO&opage=2",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85124895169",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "Data by Country: Norway. (8 July 2020, date last accessed)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Common European Drug Database (CEDD)",
                                "ce:indexed-name": "Common European Drug Database (CEDD)"
                            }}
                        },
                        "ce:source-text": "Common European Drug Database (CEDD). Data by Country: Norway. http://cedd.oep.hu/drugs.tib?s=drug-database&mode=country&f=cedddr ug1&id=8lkdbdqvvfq2glq8&portallang=en&NO_currentletter=Galcountry=NO&opage=2 (8 July 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Norwegian Medicines Agency. Database-Approved and Marketed Pharmaceuticals. https://www.legemiddelsok.no/sider/default.aspx?searc hquery=glucosamine&f=Han;MtI;Vir;ATC;Var;Mar;Mid;Avr;gen;par;&p ane=0 (4 August 2020, date last accessed).",
                        "@id": "25",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.legemiddelsok.no/sider/default.aspx?searchquery=glucosamine&f=Han;MtI;Vir;ATC;Var;Mar;Mid;Avr;gen;par;&pane=0",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "84880314469",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "(4 August 2020, date last accessed)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Norwegian Medicines Agency",
                                "ce:indexed-name": "Norwegian Medicines Agency"
                            }},
                            "ref-sourcetitle": "Database-Approved and Marketed Pharmaceuticals"
                        },
                        "ce:source-text": "Norwegian Medicines Agency. Database-Approved and Marketed Pharmaceuticals. https://www.legemiddelsok.no/sider/default.aspx?searc hquery=glucosamine&f=Han;MtI;Vir;ATC;Var;Mar;Mid;Avr;gen;par;&p ane=0 (4 August 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Food and Drug Administration Philippines. Registered Drugs: List of All Registered Drugs for Human Use. https://ww2.fda.gov.ph/index.php/ consumers-corner/registered-drugs-2?start=8800 (20 June 2020, date last accessed).",
                        "@id": "26",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://ww2.fda.gov.ph/index.php/consumers-corner/registered-drugs-2?start=8800",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85124880484",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "(20 June 2020, date last accessed)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Food and Drug Administration Philippines",
                                "ce:indexed-name": "Food and Drug Administration Philippines"
                            }},
                            "ref-sourcetitle": "Registered Drugs: List of All Registered Drugs for Human Use"
                        },
                        "ce:source-text": "Food and Drug Administration Philippines. Registered Drugs: List of All Registered Drugs for Human Use. https://ww2.fda.gov.ph/index.php/ consumers-corner/registered-drugs-2?start=8800 (20 June 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Philippine National Formulary Secretariat. Philippines National Formulary Essential Medicines List 8th Edition 2019. https:// pharmadiv.doh.gov.ph/phil-national-formulary (10 July 2020, date last accessed).",
                        "@id": "27",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://pharmadiv.doh.gov.ph/phil-national-formulary",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85124893636",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "(10 July 2020, date last accessed)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Philippine National Formulary Secretariat",
                                "ce:indexed-name": "Philippine National Formulary Secretariat"
                            }},
                            "ref-sourcetitle": "Philippines National Formulary Essential Medicines List 8th Edition 2019"
                        },
                        "ce:source-text": "Philippine National Formulary Secretariat. Philippines National Formulary Essential Medicines List 8th Edition 2019. https:// pharmadiv.doh.gov.ph/phil-national-formulary (10 July 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Ministry of Health. Drug Subsidies & Schemes https://www.moh.gov.sg/ content/moh_web/home/costs_and_financing/schemes_subsidies/drug_ subsidies.html (29 June 2020, date last accessed).",
                        "@id": "28",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.moh.gov.sg/content/moh_web/home/costs_and_financing/schemes_subsidies/drug_subsidies.html",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85106287333",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "Ministry of Health. (29 June 2020, date last accessed)",
                            "ref-sourcetitle": "Drug Subsidies & Schemes"
                        },
                        "ce:source-text": "Ministry of Health. Drug Subsidies & Schemes https://www.moh.gov.sg/ content/moh_web/home/costs_and_financing/schemes_subsidies/drug_ subsidies.html (29 June 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Ibargoyen-Roteta N, Mateos Del Pino M, GutiÃ©rrez-Ibarluzea I et al. Variability in the prescription of drugs with uncertain effectiveness. The case of SYSADOA in the Basque Country. GMS Health Technol Assess 2018; 14: Doc01. http://doi.org/10.3205/hta000130",
                        "@id": "29",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.3205/hta000130",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Variability in the prescription of drugs with uncertain effectiveness. The case of SYSADOA in the Basque Country"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.3205/hta000130",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "85082881975",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "14"},
                                "pagerange": {"@first": "Doc01"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N",
                                        "@_fa": "true",
                                        "ce:surname": "Ibargoyen-Roteta",
                                        "ce:indexed-name": "Ibargoyen-Roteta N"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Mateos Del Pino",
                                        "ce:indexed-name": "Mateos Del Pino M"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "I",
                                        "@_fa": "true",
                                        "ce:surname": "GutiÃ©rrez-Ibarluzea",
                                        "ce:indexed-name": "Gutierrez-Ibarluzea I"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "GMS Health Technol Assess"
                        },
                        "ce:source-text": "Ibargoyen-Roteta N, Mateos Del Pino M, GutiÃ©rrez-Ibarluzea I et al. Variability in the prescription of drugs with uncertain effectiveness. The case of SYSADOA in the Basque Country. GMS Health Technol Assess 2018; 14: Doc01. http://doi.org/10.3205/hta000130"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "The Swedish Dental and Pharmaceutical Reimbursement Agency (TLV). Glucosamine Excluded from the Reimbursement System. https://www. tlv.se/download/18.467926b615d084471ac33d03/1510316367373/ sammanfattning/dglukosaminer-100216.pdf (8 July 2020, date last accessed).",
                        "@id": "30",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.tlv.se/download/18.467926b615d084471ac33d03/1510316367373/sammanfattning/dglukosaminer-100216.pdf",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85124883815",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "(8 July 2020, date last accessed)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "The Swedish Dental and Pharmaceutical Reimbursement Agency (TLV)",
                                "ce:indexed-name": "The Swedish Dental and Pharmaceutical Reimbursement Agency (TLV)"
                            }},
                            "ref-sourcetitle": "Glucosamine Excluded from the Reimbursement System"
                        },
                        "ce:source-text": "The Swedish Dental and Pharmaceutical Reimbursement Agency (TLV). Glucosamine Excluded from the Reimbursement System. https://www. tlv.se/download/18.467926b615d084471ac33d03/1510316367373/ sammanfattning/dglukosaminer-100216.pdf (8 July 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Pharmaceutical Services Negotiating Committee (PSNC). Change in the Classification of Certain Glucosamine Containing Products. https://psnc.org.uk/our-news/change-in-the-classification-of-certainglucosaminecontaining-products/ (1 August 2020, date last accessed).",
                        "@id": "31",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://psnc.org.uk/our-news/change-in-the-classification-of-certainglucosaminecontaining-products/",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85124881403",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "(1 August 2020, date last accessed)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Pharmaceutical Services Negotiating Committee (PSNC)",
                                "ce:indexed-name": "Pharmaceutical Services Negotiating Committee (PSNC)"
                            }},
                            "ref-sourcetitle": "Change in the Classification of Certain Glucosamine Containing Products"
                        },
                        "ce:source-text": "Pharmaceutical Services Negotiating Committee (PSNC). Change in the Classification of Certain Glucosamine Containing Products. https://psnc.org.uk/our-news/change-in-the-classification-of-certainglucosaminecontaining-products/ (1 August 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "The National Institute for Health and Care Excellence (NICE). British National Formulary 76, September 2018-March 2019. London: GGP Media GmbH.",
                        "@id": "32",
                        "ref-info": {
                            "refd-itemidlist": {"itemid": {
                                "$": "85124903431",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "London: GGP Media GmbH",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "The National Institute for Health and Care Excellence (NICE)",
                                "ce:indexed-name": "The National Institute for Health and Care Excellence (NICE)"
                            }},
                            "ref-sourcetitle": "British National Formulary 76, September 2018-March 2019"
                        },
                        "ce:source-text": "The National Institute for Health and Care Excellence (NICE). British National Formulary 76, September 2018-March 2019. London: GGP Media GmbH."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "The Swedish Dental and Pharmaceutical Reimbursement Agency (TLV). Glucosamine Excluded from the Reimbursement System. https://www. tlv.se/download/18.467926b615d084471ac33d03/1510316367373/ sammanfattning/dglukosaminer-100216.pdf (6 August 2020, date last accessed).",
                        "@id": "33",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.tlv.se/download/18.467926b615d084471ac33d03/1510316367373/sammanfattning/dglukosaminer-100216.pdf",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85124883815",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "(6 August 2020, date last accessed)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "The Swedish Dental and Pharmaceutical Reimbursement Agency (TLV)",
                                "ce:indexed-name": "The Swedish Dental and Pharmaceutical Reimbursement Agency (TLV)"
                            }},
                            "ref-sourcetitle": "Glucosamine Excluded from the Reimbursement System"
                        },
                        "ce:source-text": "The Swedish Dental and Pharmaceutical Reimbursement Agency (TLV). Glucosamine Excluded from the Reimbursement System. https://www. tlv.se/download/18.467926b615d084471ac33d03/1510316367373/ sammanfattning/dglukosaminer-100216.pdf (6 August 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Danish Medicines Agency. The Reimbursement for Glucosamine Is Removed on 28 November 2011. https://laegemiddelstyrelsen.dk/en/ news/reassessment-of-reimbursement-of-medicines-news-archives/thereimbursement-for-glucosamine-is-removed-on-28-november-2011/ (2 June 2020, date last accessed).",
                        "@id": "34",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://laegemiddelstyrelsen.dk/en/news/reassessment-of-reimbursement-of-medicines-news-archives/thereimbursement-for-glucosamine-is-removed-on-28-november-2011/",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85124874088",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "(2 June 2020, date last accessed)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Danish Medicines Agency",
                                "ce:indexed-name": "Danish Medicines Agency"
                            }},
                            "ref-sourcetitle": "The Reimbursement for Glucosamine Is Removed on 28 November 2011"
                        },
                        "ce:source-text": "Danish Medicines Agency. The Reimbursement for Glucosamine Is Removed on 28 November 2011. https://laegemiddelstyrelsen.dk/en/ news/reassessment-of-reimbursement-of-medicines-news-archives/thereimbursement-for-glucosamine-is-removed-on-28-november-2011/ (2 June 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "National Centre for Pharmacoeconomics (NCPE) Ireland. Economic Evaluation of Glucosamine Sulfate (DONAÂ® ) for the Treatment of Osteoarthritis in the Irish Healthcare Setting. http://www.ncpe.ie/drugs/ glucosamine-sulfate-dona/ (13 July 2020, date last accessed).",
                        "@id": "35",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "http://www.ncpe.ie/drugs/glucosamine-sulfate-dona/",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85124883973",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "(13 July 2020, date last accessed)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "National Centre for Pharmacoeconomics (NCPE) Ireland",
                                "ce:indexed-name": "National Centre for Pharmacoeconomics (NCPE) Ireland"
                            }},
                            "ref-sourcetitle": "Economic Evaluation of Glucosamine Sulfate (DONAÂ® ) for the Treatment of Osteoarthritis in the Irish Healthcare Setting"
                        },
                        "ce:source-text": "National Centre for Pharmacoeconomics (NCPE) Ireland. Economic Evaluation of Glucosamine Sulfate (DONAÂ® ) for the Treatment of Osteoarthritis in the Irish Healthcare Setting. http://www.ncpe.ie/drugs/ glucosamine-sulfate-dona/ (13 July 2020, date last accessed)."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Galvin R, Cousins G, Boland F et al. Prescribing patterns of glucosamine in an older population: a national cohort study. BMC Complement Altern Med 2013; 13: 316. http://doi.org/10.1186/1472-6882-13-316",
                        "@id": "36",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.1186/1472-6882-13-316",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Prescribing patterns of glucosamine in an older population: a national cohort study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1186/1472-6882-13-316",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "84887325166",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "13"},
                                "pagerange": {"@first": "316"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R",
                                        "@_fa": "true",
                                        "ce:surname": "Galvin",
                                        "ce:indexed-name": "Galvin R"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "G",
                                        "@_fa": "true",
                                        "ce:surname": "Cousins",
                                        "ce:indexed-name": "Cousins G"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F",
                                        "@_fa": "true",
                                        "ce:surname": "Boland",
                                        "ce:indexed-name": "Boland F"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "BMC Complement Altern Med"
                        },
                        "ce:source-text": "Galvin R, Cousins G, Boland F et al. Prescribing patterns of glucosamine in an older population: a national cohort study. BMC Complement Altern Med 2013; 13: 316. http://doi.org/10.1186/1472-6882-13-316"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Lopes Vaz A. Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthrosis of the knee in out-patients. Curr Med Res Opin 1982; 8: 145-9. http://doi. org/10.1185/03007998209112375",
                        "@id": "37",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "1982"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.1185/03007998209112375",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthrosis of the knee in out-patients"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1185/03007998209112375",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "0020318524",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "8"},
                                "pagerange": {
                                    "@first": "145",
                                    "@last": "149"
                                }
                            },
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "A.",
                                "@_fa": "true",
                                "ce:surname": "Lopes Vaz",
                                "ce:indexed-name": "Lopes Vaz A."
                            }]},
                            "ref-sourcetitle": "Curr Med Res Opin"
                        },
                        "ce:source-text": "Lopes Vaz A. Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthrosis of the knee in out-patients. Curr Med Res Opin 1982; 8: 145-9. http://doi. org/10.1185/03007998209112375"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "MÃ¼ller-Fassbender H, Bach GL, Haase W et al. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage 1994; 2: 61-9. http://doi.org/10.1016/s1063-4584(05)80007-x",
                        "@id": "38",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "1994"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.1016/s1063-4584(05)80007-x",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1016/s1063-4584(05)80007-x",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "0028362757",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "2"},
                                "pagerange": {
                                    "@first": "61",
                                    "@last": "69"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "H",
                                        "@_fa": "true",
                                        "ce:surname": "MÃ¼ller-Fassbender",
                                        "ce:indexed-name": "Muller-Fassbender H"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "GL",
                                        "@_fa": "true",
                                        "ce:surname": "Bach",
                                        "ce:indexed-name": "Bach GL"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "W",
                                        "@_fa": "true",
                                        "ce:surname": "Haase",
                                        "ce:indexed-name": "Haase W"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Osteoarthritis Cartilage"
                        },
                        "ce:source-text": "MÃ¼ller-Fassbender H, Bach GL, Haase W et al. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage 1994; 2: 61-9. http://doi.org/10.1016/s1063-4584(05)80007-x"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Reginster JY, Deroisy R, Rovati LC et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebocontrolled clinical trial. Lancet 2001; 357: 251-6. http://doi.org/10.1016/ S0140-6736(00)03610-2",
                        "@id": "39",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2001"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.1016/S0140-6736(00)03610-2",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebocontrolled clinical trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1016/S0140-6736(00)03610-2",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "0035956653",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "357"},
                                "pagerange": {
                                    "@first": "251",
                                    "@last": "256"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "JY",
                                        "@_fa": "true",
                                        "ce:surname": "Reginster",
                                        "ce:indexed-name": "Reginster JY"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R",
                                        "@_fa": "true",
                                        "ce:surname": "Deroisy",
                                        "ce:indexed-name": "Deroisy R"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "LC",
                                        "@_fa": "true",
                                        "ce:surname": "Rovati",
                                        "ce:indexed-name": "Rovati LC"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet"
                        },
                        "ce:source-text": "Reginster JY, Deroisy R, Rovati LC et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebocontrolled clinical trial. Lancet 2001; 357: 251-6. http://doi.org/10.1016/ S0140-6736(00)03610-2"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "PavelkÃ¡ K, GatterovÃ¡ J, OlejarovÃ¡ M et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebocontrolled, double-blind study. Arch Intern Med 2002; 162: 2113-23. http://doi.org/10.1001/archinte.162.18.2113",
                        "@id": "40",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2002"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.1001/archinte.162.18.2113",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebocontrolled, double-blind study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1001/archinte.162.18.2113",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "0037078298",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "162"},
                                "pagerange": {
                                    "@first": "2113",
                                    "@last": "2123"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K",
                                        "@_fa": "true",
                                        "ce:surname": "PavelkÃ¡",
                                        "ce:indexed-name": "Pavelka K"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J",
                                        "@_fa": "true",
                                        "ce:surname": "GatterovÃ¡",
                                        "ce:indexed-name": "Gatterova J"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "OlejarovÃ¡",
                                        "ce:indexed-name": "Olejarova M"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Arch Intern Med"
                        },
                        "ce:source-text": "PavelkÃ¡ K, GatterovÃ¡ J, OlejarovÃ¡ M et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebocontrolled, double-blind study. Arch Intern Med 2002; 162: 2113-23. http://doi.org/10.1001/archinte.162.18.2113"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Sawitzke AD, Shi H, Finco MF et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum 2008; 58: 3183-91. http://doi.org/10.1002/art.23973",
                        "@id": "41",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2008"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.1002/art.23973",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1002/art.23973",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "54949121728",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "58"},
                                "pagerange": {
                                    "@first": "3183",
                                    "@last": "3191"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "AD",
                                        "@_fa": "true",
                                        "ce:surname": "Sawitzke",
                                        "ce:indexed-name": "Sawitzke AD"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H",
                                        "@_fa": "true",
                                        "ce:surname": "Shi",
                                        "ce:indexed-name": "Shi H"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "MF",
                                        "@_fa": "true",
                                        "ce:surname": "Finco",
                                        "ce:indexed-name": "Finco MF"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Arthritis Rheum"
                        },
                        "ce:source-text": "Sawitzke AD, Shi H, Finco MF et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum 2008; 58: 3183-91. http://doi.org/10.1002/art.23973"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Towheed T, Maxwell L, Anastassiades TP et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005; 2: 1-77. http:// doi.org/ 10.1002/14651858.CD002946.pub2",
                        "@id": "42",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2005"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.1002/14651858.CD002946.pub2",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Glucosamine therapy for treating osteoarthritis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1002/14651858.CD002946.pub2",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "0035221023",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "2"},
                                "pagerange": {
                                    "@first": "1",
                                    "@last": "77"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "T",
                                        "@_fa": "true",
                                        "ce:surname": "Towheed",
                                        "ce:indexed-name": "Towheed T"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L",
                                        "@_fa": "true",
                                        "ce:surname": "Maxwell",
                                        "ce:indexed-name": "Maxwell L"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "TP",
                                        "@_fa": "true",
                                        "ce:surname": "Anastassiades",
                                        "ce:indexed-name": "Anastassiades TP"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cochrane Database Syst Rev"
                        },
                        "ce:source-text": "Towheed T, Maxwell L, Anastassiades TP et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005; 2: 1-77. http:// doi.org/ 10.1002/14651858.CD002946.pub2"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Matheson A, Perry C. Glucosamine: a review of its use in the management of osteoarthritis. Altern Med Rev 2004; 9: 94-95. http://doi. org/10.2165/00002512-200320140-00004",
                        "@id": "43",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2004"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.2165/00002512-200320140-00004",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Glucosamine: a review of its use in the management of osteoarthritis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.2165/00002512-200320140-00004",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "85124909706",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "9"},
                                "pagerange": {
                                    "@first": "94",
                                    "@last": "95"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "A",
                                    "@_fa": "true",
                                    "ce:surname": "Matheson",
                                    "ce:indexed-name": "Matheson A"
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "C.",
                                    "@_fa": "true",
                                    "ce:surname": "Perry",
                                    "ce:indexed-name": "Perry C."
                                }
                            ]},
                            "ref-sourcetitle": "Altern Med Rev"
                        },
                        "ce:source-text": "Matheson A, Perry C. Glucosamine: a review of its use in the management of osteoarthritis. Altern Med Rev 2004; 9: 94-95. http://doi. org/10.2165/00002512-200320140-00004"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Clegg DO, Reda DJ, Harris CL et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354: 795-808. http://doi.org/10.1056/NEJMoa052771",
                        "@id": "44",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2006"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.1056/NEJMoa052771",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1056/NEJMoa052771",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "33344461287",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "354"},
                                "pagerange": {
                                    "@first": "795",
                                    "@last": "808"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "DO",
                                        "@_fa": "true",
                                        "ce:surname": "Clegg",
                                        "ce:indexed-name": "Clegg DO"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "DJ",
                                        "@_fa": "true",
                                        "ce:surname": "Reda",
                                        "ce:indexed-name": "Reda DJ"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "CL",
                                        "@_fa": "true",
                                        "ce:surname": "Harris",
                                        "ce:indexed-name": "Harris CL"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Clegg DO, Reda DJ, Harris CL et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354: 795-808. http://doi.org/10.1056/NEJMoa052771"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Kawasaki T, Kurosawa H, Ikeda H et al. Additive effects of glucosamine or risedronate for the treatment of osteoarthritis of the knee combined with home exercise: a prospective randomized 18-month trial. J Bone Miner Metab 2008; 26: 279-87. http://doi.org/10.1007/s00774-007-0813-5",
                        "@id": "45",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2008"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.1007/s00774-007-0813-5",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Additive effects of glucosamine or risedronate for the treatment of osteoarthritis of the knee combined with home exercise: a prospective randomized 18-month trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1007/s00774-007-0813-5",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "43549096885",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "26"},
                                "pagerange": {
                                    "@first": "279",
                                    "@last": "287"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "T",
                                        "@_fa": "true",
                                        "ce:surname": "Kawasaki",
                                        "ce:indexed-name": "Kawasaki T"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H",
                                        "@_fa": "true",
                                        "ce:surname": "Kurosawa",
                                        "ce:indexed-name": "Kurosawa H"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "H",
                                        "@_fa": "true",
                                        "ce:surname": "Ikeda",
                                        "ce:indexed-name": "Ikeda H"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Bone Miner Metab"
                        },
                        "ce:source-text": "Kawasaki T, Kurosawa H, Ikeda H et al. Additive effects of glucosamine or risedronate for the treatment of osteoarthritis of the knee combined with home exercise: a prospective randomized 18-month trial. J Bone Miner Metab 2008; 26: 279-87. http://doi.org/10.1007/s00774-007-0813-5"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "BruyÃ¨re O, Altman RD, Reginster JY. Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: evidence from real-life setting trials and surveys. Semin Arthritis Rheum 2016; 45: S12-7. http://doi. org/10.1016/j.semarthrit.2015.11.011",
                        "@id": "46",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.1016/j.semarthrit.2015.11.011",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: evidence from real-life setting trials and surveys"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1016/j.semarthrit.2015.11.011",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "84958111885",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "45"},
                                "pagerange": {
                                    "@first": "S12",
                                    "@last": "S17"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "O",
                                    "@_fa": "true",
                                    "ce:surname": "BruyÃ¨re",
                                    "ce:indexed-name": "Bruyere O"
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "RD",
                                    "@_fa": "true",
                                    "ce:surname": "Altman",
                                    "ce:indexed-name": "Altman RD"
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "JY.",
                                    "@_fa": "true",
                                    "ce:surname": "Reginster",
                                    "ce:indexed-name": "Reginster JY."
                                }
                            ]},
                            "ref-sourcetitle": "Semin Arthritis Rheum"
                        },
                        "ce:source-text": "BruyÃ¨re O, Altman RD, Reginster JY. Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: evidence from real-life setting trials and surveys. Semin Arthritis Rheum 2016; 45: S12-7. http://doi. org/10.1016/j.semarthrit.2015.11.011"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Rovati LC, Girolami F, Persiani S. Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties. Ther Adv Musculoskelet Dis 2012; 4: 167-80. http://doi. org/10.1177/1759720X12437753",
                        "@id": "47",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2012"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.1177/1759720X12437753",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1177/1759720X12437753",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "84868647956",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "4"},
                                "pagerange": {
                                    "@first": "167",
                                    "@last": "180"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "LC",
                                    "@_fa": "true",
                                    "ce:surname": "Rovati",
                                    "ce:indexed-name": "Rovati LC"
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "F",
                                    "@_fa": "true",
                                    "ce:surname": "Girolami",
                                    "ce:indexed-name": "Girolami F"
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "S.",
                                    "@_fa": "true",
                                    "ce:surname": "Persiani",
                                    "ce:indexed-name": "Persiani S."
                                }
                            ]},
                            "ref-sourcetitle": "Ther Adv Musculoskelet Dis"
                        },
                        "ce:source-text": "Rovati LC, Girolami F, Persiani S. Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties. Ther Adv Musculoskelet Dis 2012; 4: 167-80. http://doi. org/10.1177/1759720X12437753"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Eriksen P, Bartels EM, Altman RD et al. Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta-analysis of placebo-controlled trials. Arthritis Care Res (Hoboken) 2014; 66: 1844-55. http://doi.org/10.1002/acr.22376",
                        "@id": "48",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.1002/acr.22376",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta-analysis of placebo-controlled trials"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1002/acr.22376",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "84912119164",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "66"},
                                "pagerange": {
                                    "@first": "1844",
                                    "@last": "1855"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P",
                                        "@_fa": "true",
                                        "ce:surname": "Eriksen",
                                        "ce:indexed-name": "Eriksen P"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "EM",
                                        "@_fa": "true",
                                        "ce:surname": "Bartels",
                                        "ce:indexed-name": "Bartels EM"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "RD",
                                        "@_fa": "true",
                                        "ce:surname": "Altman",
                                        "ce:indexed-name": "Altman RD"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Arthritis Care Res (Hoboken)"
                        },
                        "ce:source-text": "Eriksen P, Bartels EM, Altman RD et al. Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta-analysis of placebo-controlled trials. Arthritis Care Res (Hoboken) 2014; 66: 1844-55. http://doi.org/10.1002/acr.22376"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Kucharz EJ, Kovalenko V, SzÃ¡ntÃ³ S et al. A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes. Curr Med Res Opin 2016; 32: 997-1004. http://doi.org/10.1185/03007995.2016.1154521",
                        "@id": "49",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.1185/03007995.2016.1154521",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1185/03007995.2016.1154521",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "84959203058",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "32"},
                                "pagerange": {
                                    "@first": "997",
                                    "@last": "1004"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "EJ",
                                        "@_fa": "true",
                                        "ce:surname": "Kucharz",
                                        "ce:indexed-name": "Kucharz EJ"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "V",
                                        "@_fa": "true",
                                        "ce:surname": "Kovalenko",
                                        "ce:indexed-name": "Kovalenko V"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "SzÃ¡ntÃ³",
                                        "ce:indexed-name": "Szanto S"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Curr Med Res Opin"
                        },
                        "ce:source-text": "Kucharz EJ, Kovalenko V, SzÃ¡ntÃ³ S et al. A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes. Curr Med Res Opin 2016; 32: 997-1004. http://doi.org/10.1185/03007995.2016.1154521"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Bruyere O, Pavelka K, Rovati LC et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage 2008; 16: 254-60. http://doi.org/10.1016/j.joca.2007.06.011",
                        "@id": "50",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2008"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.1016/j.joca.2007.06.011",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1016/j.joca.2007.06.011",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "38949175302",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "16"},
                                "pagerange": {
                                    "@first": "254",
                                    "@last": "260"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "O",
                                        "@_fa": "true",
                                        "ce:surname": "Bruyere",
                                        "ce:indexed-name": "Bruyere O"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K",
                                        "@_fa": "true",
                                        "ce:surname": "Pavelka",
                                        "ce:indexed-name": "Pavelka K"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "LC",
                                        "@_fa": "true",
                                        "ce:surname": "Rovati",
                                        "ce:indexed-name": "Rovati LC"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Osteoarthritis Cartilage"
                        },
                        "ce:source-text": "Bruyere O, Pavelka K, Rovati LC et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage 2008; 16: 254-60. http://doi.org/10.1016/j.joca.2007.06.011"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Rovati LC, Girolami F, D'Amato M et al. Effects of glucosamine sulfate on the use of rescue non-steroidal anti-inflammatory drugs in knee osteoarthritis: results from the Pharmaco-Epidemiology of GonArthroSis (PEGASus) study. Semin Arthritis Rheum 2016; 45: S34-41. http://doi. org/10.1016/j.semarthrit.2015.10.009",
                        "@id": "51",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.1016/j.semarthrit.2015.10.009",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Effects of glucosamine sulfate on the use of rescue non-steroidal anti-inflammatory drugs in knee osteoarthritis: results from the Pharmaco-Epidemiology of GonArthroSis (PEGASus) study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1016/j.semarthrit.2015.10.009",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "84958104663",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "45"},
                                "pagerange": {
                                    "@first": "S34",
                                    "@last": "S41"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "LC",
                                        "@_fa": "true",
                                        "ce:surname": "Rovati",
                                        "ce:indexed-name": "Rovati LC"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "F",
                                        "@_fa": "true",
                                        "ce:surname": "Girolami",
                                        "ce:indexed-name": "Girolami F"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "D'Amato",
                                        "ce:indexed-name": "D'Amato M"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Semin Arthritis Rheum"
                        },
                        "ce:source-text": "Rovati LC, Girolami F, D'Amato M et al. Effects of glucosamine sulfate on the use of rescue non-steroidal anti-inflammatory drugs in knee osteoarthritis: results from the Pharmaco-Epidemiology of GonArthroSis (PEGASus) study. Semin Arthritis Rheum 2016; 45: S34-41. http://doi. org/10.1016/j.semarthrit.2015.10.009"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Anderson JW, Nicolosi RJ, Borzelleca JF. Glucosamine effects in humans: a review of effects on glucose metabolism, side effects, safety considerations and efficacy. Food Chem Toxicol 2005; 43: 187-201. http://doi. org/10.1016/j.fct.2004.11.006",
                        "@id": "52",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2005"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.1016/j.fct.2004.11.006",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Glucosamine effects in humans: a review of effects on glucose metabolism, side effects, safety considerations and efficacy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1016/j.fct.2004.11.006",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "11044229969",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "43"},
                                "pagerange": {
                                    "@first": "187",
                                    "@last": "201"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "JW",
                                    "@_fa": "true",
                                    "ce:surname": "Anderson",
                                    "ce:indexed-name": "Anderson JW"
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "RJ",
                                    "@_fa": "true",
                                    "ce:surname": "Nicolosi",
                                    "ce:indexed-name": "Nicolosi RJ"
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "JF.",
                                    "@_fa": "true",
                                    "ce:surname": "Borzelleca",
                                    "ce:indexed-name": "Borzelleca JF."
                                }
                            ]},
                            "ref-sourcetitle": "Food Chem Toxicol"
                        },
                        "ce:source-text": "Anderson JW, Nicolosi RJ, Borzelleca JF. Glucosamine effects in humans: a review of effects on glucose metabolism, side effects, safety considerations and efficacy. Food Chem Toxicol 2005; 43: 187-201. http://doi. org/10.1016/j.fct.2004.11.006"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Muzzarelli RA. Chitins and chitosans as immunoadjuvants and non-allergenic drug carriers. Mar Drugs 2010; 8: 292-312. http://doi. org/10.3390/md8020292",
                        "@id": "53",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2010"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.3390/md8020292",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Chitins and chitosans as immunoadjuvants and non-allergenic drug carriers"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.3390/md8020292",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "77649198518",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "8"},
                                "pagerange": {
                                    "@first": "292",
                                    "@last": "312"
                                }
                            },
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "RA.",
                                "@_fa": "true",
                                "ce:surname": "Muzzarelli",
                                "ce:indexed-name": "Muzzarelli RA."
                            }]},
                            "ref-sourcetitle": "Mar Drugs"
                        },
                        "ce:source-text": "Muzzarelli RA. Chitins and chitosans as immunoadjuvants and non-allergenic drug carriers. Mar Drugs 2010; 8: 292-312. http://doi. org/10.3390/md8020292"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Scholtissen S, BruyÃ¨re O, Neuprez A et al. Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. Int J Clin Pract 2010; 64: 756-62. http://doi. org/10.1111/j.1742-1241.2010.02362.x",
                        "@id": "54",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2010"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.1111/j.1742-1241.2010.02362.x",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1111/j.1742-1241.2010.02362.x",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "77950645209",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "64"},
                                "pagerange": {
                                    "@first": "756",
                                    "@last": "762"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "Scholtissen",
                                        "ce:indexed-name": "Scholtissen S"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "O",
                                        "@_fa": "true",
                                        "ce:surname": "BruyÃ¨re",
                                        "ce:indexed-name": "Bruyere O"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A",
                                        "@_fa": "true",
                                        "ce:surname": "Neuprez",
                                        "ce:indexed-name": "Neuprez A"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Int J Clin Pract"
                        },
                        "ce:source-text": "Scholtissen S, BruyÃ¨re O, Neuprez A et al. Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. Int J Clin Pract 2010; 64: 756-62. http://doi. org/10.1111/j.1742-1241.2010.02362.x"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Black C, Clar C, Henderson R et al. The clinical effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of the knee: a systematic review and economic evaluation. Health Technol Assess 2009; 13: 1-148. http://doi.org/10.3310/ hta13520",
                        "@id": "55",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2009"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.3310/hta13520",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "The clinical effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of the knee: a systematic review and economic evaluation"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.3310/hta13520",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "73549124985",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "13"},
                                "pagerange": {
                                    "@first": "1",
                                    "@last": "148"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C",
                                        "@_fa": "true",
                                        "ce:surname": "Black",
                                        "ce:indexed-name": "Black C"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C",
                                        "@_fa": "true",
                                        "ce:surname": "Clar",
                                        "ce:indexed-name": "Clar C"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R",
                                        "@_fa": "true",
                                        "ce:surname": "Henderson",
                                        "ce:indexed-name": "Henderson R"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Health Technol Assess"
                        },
                        "ce:source-text": "Black C, Clar C, Henderson R et al. The clinical effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of the knee: a systematic review and economic evaluation. Health Technol Assess 2009; 13: 1-148. http://doi.org/10.3310/ hta13520"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Chaiyakunapruk N, Saokaew S, Pansang S. Cost-effectiveness analysis of glucosamine sulphate for the treatment of osteoarthritis in Thailand. Value in Health 2010; 13: A502. http://doi. org/10.1111/j.1524-4733.2010.00793_1.x",
                        "@id": "56",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2010"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.1111/j.1524-4733.2010.00793_1.x",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Cost-effectiveness analysis of glucosamine sulphate for the treatment of osteoarthritis in Thailand"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1111/j.1524-4733.2010.00793_1.x",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "85124906123",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "13"},
                                "pagerange": {"@first": "A502"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "N",
                                    "@_fa": "true",
                                    "ce:surname": "Chaiyakunapruk",
                                    "ce:indexed-name": "Chaiyakunapruk N"
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "S",
                                    "@_fa": "true",
                                    "ce:surname": "Saokaew",
                                    "ce:indexed-name": "Saokaew S"
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "S.",
                                    "@_fa": "true",
                                    "ce:surname": "Pansang",
                                    "ce:indexed-name": "Pansang S."
                                }
                            ]},
                            "ref-sourcetitle": "Value in Health"
                        },
                        "ce:source-text": "Chaiyakunapruk N, Saokaew S, Pansang S. Cost-effectiveness analysis of glucosamine sulphate for the treatment of osteoarthritis in Thailand. Value in Health 2010; 13: A502. http://doi. org/10.1111/j.1524-4733.2010.00793_1.x"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "National Collaborating Centre for Chronic Conditions and National Institute for Clinical Excellence. Osteoarthritis: National Clinical Guidelines for Care and Management in Adults. London: Royal College of Physicians, 2008.",
                        "@id": "57",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2008"},
                            "refd-itemidlist": {"itemid": {
                                "$": "46149097354",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "National Collaborating Centre for Chronic Conditions and National Institute for Clinical Excellence. London: Royal College of Physicians",
                            "ref-sourcetitle": "Osteoarthritis: National Clinical Guidelines for Care and Management in Adults"
                        },
                        "ce:source-text": "National Collaborating Centre for Chronic Conditions and National Institute for Clinical Excellence. Osteoarthritis: National Clinical Guidelines for Care and Management in Adults. London: Royal College of Physicians, 2008."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "BruyÃ¨re O, Reginster JY, Honvo G et al. Cost-effectiveness evaluation of glucosamine for osteoarthritis based on simulation of individual patient data obtained from aggregated data in published studies. Aging Clin Exp Res 2019; 31: 881-7. http://doi.org/10.1007/ s40520-019-01138-1",
                        "@id": "58",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://doi.org/10.1007/s40520-019-01138-1",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Cost-effectiveness evaluation of glucosamine for osteoarthritis based on simulation of individual patient data obtained from aggregated data in published studies"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1007/s40520-019-01138-1",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "85061381747",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "31"},
                                "pagerange": {
                                    "@first": "881",
                                    "@last": "887"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "O",
                                        "@_fa": "true",
                                        "ce:surname": "BruyÃ¨re",
                                        "ce:indexed-name": "Bruyere O"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "JY",
                                        "@_fa": "true",
                                        "ce:surname": "Reginster",
                                        "ce:indexed-name": "Reginster JY"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G",
                                        "@_fa": "true",
                                        "ce:surname": "Honvo",
                                        "ce:indexed-name": "Honvo G"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Aging Clin Exp Res"
                        },
                        "ce:source-text": "BruyÃ¨re O, Reginster JY, Honvo G et al. Cost-effectiveness evaluation of glucosamine for osteoarthritis based on simulation of individual patient data obtained from aggregated data in published studies. Aging Clin Exp Res 2019; 31: 881-7. http://doi.org/10.1007/ s40520-019-01138-1"
                    }
                ]
            }}
        }
    },
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60028190",
        "affilname": "Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
        "affiliation-country": "Thailand"
    },
    "coredata": {
        "srctype": "j",
        "eid": "2-s2.0-85124908972",
        "dc:description": "Objectives: To examine the relationship among Health Technology Assessment (HTA) evidence, regulatory classification and reimbursement of health products using glucosamine as a case study. Data of HTA evidence, regulatory classification and reimbursement of glucosamine from 13 countries were extracted from official government websites and peer-reviewed journal articles. Role and responsibility of HTA in each country along as well as the regulatory approval process and reimbursement status of health products were reviewed. The case of glucosamine was then analysed to explore the regulatory classification, reimbursement and its HTA evidence from past to present. Key findings: For regulatory classification, we found that glucosamine is classified as either medicine (9 from 13 countries) or a dietary supplement (4 from 13 countries) depends on where glucosamine is seeking its market approval. Reimbursement also differs among the countries. We summarized the key factors that could be the cause of these variations. First, the clinical evidence of glucosamine is still in question especially its efficacy and as a results its cost-effectiveness. This evidence is important for policy consideration. Secondly, different level of HTA approach in each healthcare system and country context effect on how HTA evidence is utilized and synthesized. Lastly, company's strategic positioning is the first key stakeholder to decide whether their product would be registered as medicine or dietary supplement. Summary: The variation of HTA evidence in a diverse healthcare system affects regulatory classifications and reimbursement. This can result in different levels of patient access to health products.",
        "prism:coverDate": "2021-11-01",
        "prism:aggregationType": "Journal",
        "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85124908972",
        "dc:creator": {"author": [{
            "ce:given-name": "Parnnaphat",
            "preferred-name": {
                "ce:given-name": "Parnnaphat",
                "ce:initials": "P.",
                "ce:surname": "Luksameesate",
                "ce:indexed-name": "Luksameesate P."
            },
            "@seq": "1",
            "ce:initials": "P.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60028190",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"
            },
            "ce:surname": "Luksameesate",
            "@auid": "57458762900",
            "author-url": "https://api.elsevier.com/content/author/author_id/57458762900",
            "ce:indexed-name": "Luksameesate P."
        }]},
        "link": [
            {
                "@_fa": "true",
                "@rel": "self",
                "@href": "https://api.elsevier.com/content/abstract/scopus_id/85124908972"
            },
            {
                "@_fa": "true",
                "@rel": "scopus",
                "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85124908972&origin=inward"
            },
            {
                "@_fa": "true",
                "@rel": "scopus-citedby",
                "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85124908972&origin=inward"
            }
        ],
        "source-id": "19700201423",
        "citedby-count": "2",
        "prism:volume": "12",
        "subtype": "re",
        "dc:title": "Health Technology Assessment (HTA) evidence, regulatory classification and reimbursement of medicine: The case of glucosamine",
        "openaccess": "0",
        "prism:issn": "17598893 17598885",
        "publishercopyright": "Â© 2021 The Author(s). Published by Oxford University Press on behalf of the Royal Pharmaceutical Society. All rights reserved",
        "prism:issueIdentifier": "4",
        "subtypeDescription": "Review",
        "prism:publicationName": "Journal of Pharmaceutical Health Services Research",
        "prism:pageRange": "600-606",
        "prism:endingPage": "606",
        "openaccessFlag": "false",
        "prism:doi": "10.1093/jphsr/rmab058",
        "prism:startingPage": "600",
        "dc:identifier": "SCOPUS_ID:85124908972",
        "dc:publisher": "Oxford University Press"
    },
    "idxterms": null,
    "language": {"@xml:lang": "eng"},
    "authkeywords": {"author-keyword": [
        {
            "@_fa": "true",
            "$": "glucosamine"
        },
        {
            "@_fa": "true",
            "$": "Health Technology Assessment (HTA)"
        },
        {
            "@_fa": "true",
            "$": "osteoarthritis"
        },
        {
            "@_fa": "true",
            "$": "regulatory classification"
        },
        {
            "@_fa": "true",
            "$": "reimbursement"
        }
    ]},
    "subject-areas": {"subject-area": [
        {
            "@_fa": "true",
            "$": "Pharmacy",
            "@code": "3611",
            "@abbrev": "HEAL"
        },
        {
            "@_fa": "true",
            "$": "Economics, Econometrics and Finance (miscellaneous)",
            "@code": "2001",
            "@abbrev": "ECON"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology, Toxicology and Pharmaceutics (miscellaneous)",
            "@code": "3001",
            "@abbrev": "PHAR"
        }
    ]},
    "authors": {"author": [
        {
            "ce:given-name": "Parnnaphat",
            "preferred-name": {
                "ce:given-name": "Parnnaphat",
                "ce:initials": "P.",
                "ce:surname": "Luksameesate",
                "ce:indexed-name": "Luksameesate P."
            },
            "@seq": "1",
            "ce:initials": "P.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60028190",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"
            },
            "ce:surname": "Luksameesate",
            "@auid": "57458762900",
            "author-url": "https://api.elsevier.com/content/author/author_id/57458762900",
            "ce:indexed-name": "Luksameesate P."
        },
        {
            "ce:given-name": "Suthira",
            "preferred-name": {
                "ce:given-name": "Suthira",
                "ce:initials": "S.",
                "ce:surname": "Taychakhoonavudh",
                "ce:indexed-name": "Taychakhoonavudh S."
            },
            "@seq": "2",
            "ce:initials": "S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60028190",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"
            },
            "ce:surname": "Taychakhoonavudh",
            "@auid": "56196894400",
            "author-url": "https://api.elsevier.com/content/author/author_id/56196894400",
            "ce:indexed-name": "Taychakhoonavudh S."
        }
    ]}
}}